Terms: = Ovarian cancer AND MYB, c-myb_CDS, 4602, ENSG00000118513, P10242, efg, Cmyb, c-myb
27 results:
1. LncRNA
Wang J; Han Y; Zhang T; Li J; Xu B
Front Biosci (Landmark Ed); 2023 Oct; 28(10):270. PubMed ID: 37919051
[TBL] [Abstract] [Full Text] [Related]
2. A Comprehensive Analysis of Prognostic Indicators in Serous ovarian cancer Based on Leukocyte Migration and Immune Microenvironment.
Pan J; Chen X; Yang L; Song Y; Liu J; Li L; Lin Y; Tang L; Qiu S; Xu Q
Front Biosci (Landmark Ed); 2023 Jun; 28(6):130. PubMed ID: 37395023
[TBL] [Abstract] [Full Text] [Related]
3. Clinicopathologic significance and race-specific prognostic association of myb overexpression in ovarian cancer.
Miree O; Srivastava SK; Khan MA; Sameeta F; Acharya S; Ndetan H; Singh KP; Hertweck KL; Dasgupta S; da Silva LM; Rocconi RP; Carter JE; Singh S; Singh AP
Sci Rep; 2021 Jun; 11(1):12901. PubMed ID: 34145334
[TBL] [Abstract] [Full Text] [Related]
4. Extracellular vesicle-encapsulated microRNA-424 exerts inhibitory function in ovarian cancer by targeting myb.
Li P; Xin H; Lu L
J Transl Med; 2021 Jan; 19(1):4. PubMed ID: 33407591
[TBL] [Abstract] [Full Text] [Related]
5. Transcriptome sequencing identifies genes associated with invasion of ovarian cancer.
Peng X; Yu M; Chen J
J Int Med Res; 2020 Sep; 48(9):300060520950912. PubMed ID: 32878513
[TBL] [Abstract] [Full Text] [Related]
6. Regulation of myb mediated cisplatin resistance of ovarian cancer cells involves miR-21-wnt signaling axis.
Zhang XY; Li YF; Ma H; Gao YH
Sci Rep; 2020 Apr; 10(1):6893. PubMed ID: 32327705
[TBL] [Abstract] [Full Text] [Related]
7. MicroRNA-150-5p promotes cell motility by inhibiting c-myb-mediated Slug suppression and is a prognostic biomarker for recurrent ovarian cancer.
Tung CH; Kuo LW; Huang MF; Wu YY; Tsai YT; Wu JE; Hsu KF; Chen YL; Hong TM
Oncogene; 2020 Jan; 39(4):862-876. PubMed ID: 31570789
[TBL] [Abstract] [Full Text] [Related]
8. Modulation of myb-induced NF-kB -STAT3 signaling and resulting cisplatin resistance in ovarian cancer by dietary factors.
Tian M; Tian D; Qiao X; Li J; Zhang L
J Cell Physiol; 2019 Nov; 234(11):21126-21134. PubMed ID: 31037726
[TBL] [Abstract] [Full Text] [Related]
9. The cell cycle regulatory DREAM complex is disrupted by high expression of oncogenic B-myb.
Iness AN; Felthousen J; Ananthapadmanabhan V; Sesay F; Saini S; Guiley KZ; Rubin SM; Dozmorov M; Litovchick L
Oncogene; 2019 Feb; 38(7):1080-1092. PubMed ID: 30206359
[TBL] [Abstract] [Full Text] [Related]
10. The activation of microRNA-520h-associated TGF-β1/c-myb/Smad7 axis promotes epithelial ovarian cancer progression.
Zhang J; Liu W; Shen F; Ma X; Liu X; Tian F; Zeng W; Xi X; Lin Y
Cell Death Dis; 2018 Aug; 9(9):884. PubMed ID: 30158641
[TBL] [Abstract] [Full Text] [Related]
11. miR-150 Suppresses Tumor Growth in Melanoma Through Downregulation of myb.
Sun X; Zhang C; Cao Y; Liu E
Oncol Res; 2019 Feb; 27(3):317-323. PubMed ID: 29690954
[TBL] [Abstract] [Full Text] [Related]
12. The functional consequences and prognostic value of dosage sensitivity in ovarian cancer.
Yan Z; Liu Y; Wei Y; Zhao N; Zhang Q; Wu C; Chang Z; Xu Y
Mol Biosyst; 2017 Jan; 13(2):380-391. PubMed ID: 28067383
[TBL] [Abstract] [Full Text] [Related]
13. A Systematic Analysis of Negative Growth Control Implicates the DREAM Complex in cancer Cell Dormancy.
MacDonald J; Ramos-Valdes Y; Perampalam P; Litovchick L; DiMattia GE; Dick FA
Mol Cancer Res; 2017 Apr; 15(4):371-381. PubMed ID: 28031411
[TBL] [Abstract] [Full Text] [Related]
14. Gene expression profiling analysis of the role of miR-22 in clear cell ovarian cancer.
Zhen YB; Guo XL; Xu B; Zhao HW; Xu CJ
Neoplasma; 2016; 63(6):856-864. PubMed ID: 27565323
[TBL] [Abstract] [Full Text] [Related]
15. Integrative genomic analyses of the histamine H1 receptor and its role in cancer prediction.
Wang M; Wei X; Shi L; Chen B; Zhao G; Yang H
Int J Mol Med; 2014 Apr; 33(4):1019-26. PubMed ID: 24535227
[TBL] [Abstract] [Full Text] [Related]
16. Whole exome sequencing of adenoid cystic carcinoma.
Stephens PJ; Davies HR; Mitani Y; Van Loo P; Shlien A; Tarpey PS; Papaemmanuil E; Cheverton A; Bignell GR; Butler AP; Gamble J; Gamble S; Hardy C; Hinton J; Jia M; Jayakumar A; Jones D; Latimer C; McLaren S; McBride DJ; Menzies A; Mudie L; Maddison M; Raine K; Nik-Zainal S; O'Meara S; Teague JW; Varela I; Wedge DC; Whitmore I; Lippman SM; McDermott U; Stratton MR; Campbell PJ; El-Naggar AK; Futreal PA
J Clin Invest; 2013 Jul; 123(7):2965-8. PubMed ID: 23778141
[TBL] [Abstract] [Full Text] [Related]
17. [Novel role of growth factors in ovary function].
Amsterdam A
Harefuah; 2010 Dec; 149(12):789-93, 811, 810. PubMed ID: 21916103
[TBL] [Abstract] [Full Text] [Related]
18. Erythroblastic sarcoma presenting as bilateral ovarian masses in an infant with pure erythroid leukemia.
Wang HY; Huang LJ; Liu Z; Garcia R; Li S; Galliani CA
Hum Pathol; 2011 May; 42(5):749-58. PubMed ID: 21237494
[TBL] [Abstract] [Full Text] [Related]
19. [Primary fallopian tube carcinoma].
Mladenović-Segedi L
Med Pregl; 2009; 62(1-2):31-6. PubMed ID: 19514598
[TBL] [Abstract] [Full Text] [Related]
20. Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Sabbatini P; Dupont J; Aghajanian C; Derosa F; Poynor E; Anderson S; Hensley M; Livingston P; Iasonos A; Spriggs D; McGuire W; Reinartz S; Schneider S; Grande C; Lele S; Rodabaugh K; Kepner J; Ferrone S; Odunsi K
Clin Cancer Res; 2006 Sep; 12(18):5503-10. PubMed ID: 17000686
[TBL] [Abstract] [Full Text] [Related]
[Next]
